GURUFOCUS.COM » STOCK LIST » USA » NYSE » Pfizer Inc (NYSE:PFE) » Definitions » Liabilities-to-Assets
Switch to:

Pfizer Liabilities-to-Assets

: 0.55 (As of Jun. 2022)
View and export this data going back to 1951. Start your Free Trial

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities, calculated as total liabilities divided by total asset. Pfizer's Total Liabilities for the quarter that ended in Jun. 2022 was $107,821 Mil. Pfizer's Total Assets for the quarter that ended in Jun. 2022 was $195,290 Mil. Therefore, Pfizer's Liabilities-to-Assets Ratio for the quarter that ended in Jun. 2022 was 0.55.


Pfizer Liabilities-to-Assets Historical Data

The historical data trend for Pfizer's Liabilities-to-Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pfizer Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Liabilities-to-Assets
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.58 0.60 0.62 0.59 0.57

Pfizer Quarterly Data
Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22
Liabilities-to-Assets Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.59 0.58 0.57 0.55 0.55

Competitive Comparison

For the Drug Manufacturers - General subindustry, Pfizer's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Pfizer Liabilities-to-Assets Distribution

For the Drug Manufacturers industry and Healthcare sector, Pfizer's Liabilities-to-Assets distribution charts can be found below:

* The bar in red indicates where Pfizer's Liabilities-to-Assets falls into.



Pfizer Liabilities-to-Assets Calculation

Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.

Pfizer's Liabilities-to-Assets Ratio for the fiscal year that ended in Dec. 2021 is calculated as:

Liabilities-to-Assets (A: Dec. 2021 )=Total Liabilities/Total Assets
=104014/181476
=0.57

Pfizer's Liabilities-to-Assets Ratio for the quarter that ended in Jun. 2022 is calculated as

Liabilities-to-Assets (Q: Jun. 2022 )=Total Liabilities/Total Assets
=107821/195290
=0.55

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Pfizer  (NYSE:PFE) Liabilities-to-Assets Explanation

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.


Pfizer Liabilities-to-Assets Related Terms

Thank you for viewing the detailed overview of Pfizer's Liabilities-to-Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Pfizer Business Description

Pfizer logo
Address
235 East 42nd Street, New York, NY, USA, 10017
Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 vaccine sales). While it historically sold many types of healthcare products and chemicals, now, prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, cardiovascular treatment Eliquis, and immunology drug Xeljanz. Pfizer sells these products globally, with international sales representing close to 50% of its total sales. Within international sales, emerging markets are a major contributor.
Executives
Denton David M officer: Chief Financial Officer & EVP 1000 LOWE'S BOULEVARD MOORESVILLE NC 28117
Pao William officer: Executive Vice President C/O CORPORATE SECRETARY 235 EAST 42ND STREET NEW YORK NY 10017
Mcdermott Michael officer: Executive Vice President C/O PFIZER INC. CORPORATE SECRETARY 235 EAST 42ND STREET 235 EAST 42ND STREET NY 10017
Malik Aamir officer: Executive Vice President C/O PFIZER INC. CORPORATE SECRETARY 235 EAST 42ND STREET NEW YORK NY 10017
Carapezzi William R Jr officer: Executive Vice President 600 MOUNTAIN AVENUE MURRAY HILL NJ 07921
Sahni Payal officer: Executive Vice President ATTN: PFIZER CORP. SECRETARY 235 EAST 42ND ST. NEW YORK NY 10017
Desmond-hellmann Susan director 513 PARNASSUS AVENUE S126 SAN FRANCISCO CA 94143
Hockfield Susan director GENERAL ELECTRIC COMPANY 41 FARNSWORTH STREET BOSTON MA 02210
Damico Jennifer B. officer: SVP & Controller C/O PFIZER INC. CORPORATE SECRETARY 235 EAST 42ND STREET NEW YORK NY 10017
Quincey James director THE COCA-COLA COMPANY ONE COCA-COLA PLAZA ATLANTA GA 30313
Gottlieb Scott director MOLECULAR INSIGHT PHARMACEUTICALS 160 SECOND STREET CAMBRIDGE MA 02142
Fonseca Lidia officer: Executive Vice President 358 SOUTH MAIN STREET BURLINGTON NC 27215
Goettler Michael officer: Group President 1000 MYLAN BOULEVARD CANONSBURG PA 15317
Rogers Dawn officer: Executive Vice President 235 EAST 42ND STREET NEW YORK NY 10017
Littman Dan R. director ATTN: CORPORATE SECRETARY PFIZER INC. 235 E. 42ND ST NEW YORK NY 10017

Pfizer Headlines

From GuruFocus

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)